<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2023000100024</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.22000074</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Biomarkers and treatment characteristics in metastatic colorectal cancer RASwt patients in Latin America]]></article-title>
<article-title xml:lang="es"><![CDATA[Biomarcadores y características del tratamiento en pacientes con cáncer colorrectal metastásico RAS en América Latina]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[O&#8217;Connor]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torrecillas]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Colombero]]></surname>
<given-names><![CDATA[Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sasse]]></surname>
<given-names><![CDATA[Andre]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Alexander Fleming Gastrointestinal Unit ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Centro Médico Nacional 20 de Noviembre Gastrointestinal Tumor Clinic]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Merck Department of Medical Affairs ]]></institution>
<addr-line><![CDATA[Guatemala ]]></addr-line>
<country>Guatemala</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Merck Department of Medical Affairs ]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Radium Instituto de Oncología Medical Management ]]></institution>
<addr-line><![CDATA[Campinas ]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2023</year>
</pub-date>
<volume>22</volume>
<numero>1</numero>
<fpage>24</fpage>
<lpage>33</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2023000100024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2023000100024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2023000100024&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To describe the use of biomarker testing and therapy options for RASwt patients with metastatic colorectal cancer (mCRC) in Argentina, Brazil, and Mexico during the 2017-2019 period.  Methods: We conducted descriptive analysis using datasets from privately-owned research tools.  Results: There was an increase in the use of tests performed for RAS, BRAF and MSI in all three countries. Between 2018 and 2019, RAS testing increased 15% in Argentina, 29% in Brazil and 3% in Mexico. MSI testing increased 18% in Argentina and 19% in Brazil but remained stable in Mexico at 12%. BRAF testing increased 45% in Brazil, in Argentina 46% and 29% in Mexico. Main first-line available options for m CRC were: Chemotherapy (CT), CT+ (EGFR inhibitor/anti-VEGF).  Conclusions: Given the paucity of publicly available information on access to mCRC treatments in Latin America, findings from this private data-based study may be useful for decision-making processes among healthcare institutions.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Describir del uso de biomarcadores y los tratamientos utilizados en pacientes RAS-silvestre con cáncer colorrectal metastásico (CCRm) en 3 países de Latinoamérica durante el periodo 2017-2019.  Métodos: Se realizó un análisis descriptivo de fuentes de datos estructuradas privadas para conocer el acceso a tratamientos y el uso de biomarcadores, en CCRm en Argentina, Brasil y México.  Resultados: En el periodo analizado se identificó un incrementó en el uso de pruebas para RAS, BRAF y estabilidad microsatelital en los 3 países. En relación con los tratamientos disponibles, en primera línea, las terapias más utilizadas son quimioterapia y quimioterapia en combinación con inhibidores de EGFR o con anti-VEGF.  Conclusiones: Nuestro estudio presenta datos de fuentes privadas para 3 de los países más grandes de la región que pueden ser de utilidad para la toma de decisiones en las instituciones de salud de Latinoamérica, dado que no existe suficiente información pública disponible sobre el acceso a tratamientos para CCR.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Metastatic colorectal cancer]]></kwd>
<kwd lng="en"><![CDATA[Biomarkers]]></kwd>
<kwd lng="en"><![CDATA[RAS wild type]]></kwd>
<kwd lng="en"><![CDATA[Target therapy]]></kwd>
<kwd lng="en"><![CDATA[Latin America]]></kwd>
<kwd lng="es"><![CDATA[Cáncer colorrectal metastásico]]></kwd>
<kwd lng="es"><![CDATA[Biomarcadores]]></kwd>
<kwd lng="es"><![CDATA[RAS silvestre]]></kwd>
<kwd lng="es"><![CDATA[Terapias dirigidas]]></kwd>
<kwd lng="es"><![CDATA[Latinoamérica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piñeros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abriata]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Mery]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer registration for cancer control in Latin America:a status and progress report]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2017</year>
<volume>41</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer]]></article-title>
<source><![CDATA[Chinese Clin Oncol]]></source>
<year>2019</year>
<volume>8</volume>
<page-range>49</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Valeri]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dearman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Watkins]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Starling]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting EGFR pathway in metastatic colorectal cancer-tumour heterogeniety and convergent evolution]]></article-title>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2019</year>
<volume>143</volume>
<page-range>153-63</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Modest]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Pant]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sartore-Bianchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment sequencing in metastatic colorectal cancer]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2019</year>
<volume>109</volume>
<page-range>70-83</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boleij]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tack]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kafatos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins-Anderson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tembuyser]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer:results from a Europe-wide survey of pathology centres]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2016</year>
<volume>16</volume>
<page-range>825</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YX]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprehensive review of targeted therapy for colorectal cancer]]></article-title>
<source><![CDATA[Signal Transduct Target Ther]]></source>
<year>2020</year>
<volume>5</volume>
<page-range>22</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Cutsem]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cervantes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sobrero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Van Krieken]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Aderka]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ESMO consensus guidelines for the management of patients with metastatic colorectal cancer]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2016</year>
<volume>27</volume>
<page-range>1386-422</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>National Comprehensive Cancer Network</collab>
<article-title xml:lang=""><![CDATA[Colon Cancer (version 4.2020)]]></article-title>
<source><![CDATA[Cancer Treat Research. Published online]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Philadelphia, PA ]]></publisher-loc>
<publisher-name><![CDATA[National Comprehensive Cancer Network]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>National Comprehensive Cancer Network (NCCN)</collab>
<article-title xml:lang=""><![CDATA[Genetic/Familial High-Risk Assessment8239:Colorectal (version 1.2020)]]></article-title>
<source><![CDATA[Published online]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Philadelphia, PA ]]></publisher-loc>
<publisher-name><![CDATA[National Comprehensive Cancer Network]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bekaii-Saab]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[O'Connor]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Strickler]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Malka]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Third-or later-line therapy for metastatic colorectal cancer:reviewing best practice]]></article-title>
<source><![CDATA[Clin Colorectal Cancer]]></source>
<year>2019</year>
<volume>18</volume>
<page-range>e117-29</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andre]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shiu]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Punt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer:the phase 3 KEYNOTE-177 study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2020</year>
<volume>38</volume>
<numero>18 suppl</numero>
<issue>18 suppl</issue>
<page-range>LBA4</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cremolini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rossini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dell'Aquila]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lonardi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Conca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Del Re]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan:a Phase 2 single-arm clinical trial]]></article-title>
<source><![CDATA[JAMA Oncol]]></source>
<year>2019</year>
<volume>5</volume>
<page-range>343-50</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Sandoval]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-Angulo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Magaña-Torres]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Alvizo-Rodríguez]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Plascencia]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-López]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations]]></article-title>
<source><![CDATA[J Investig Med]]></source>
<year>2020</year>
<volume>68</volume>
<page-range>985-91</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kugathasan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
<name>
<surname><![CDATA[Raghav]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Swanson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population-based screening for BRAF V600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2020</year>
<volume>26</volume>
<page-range>4599-605</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taieb]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lapeyre-Prost]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puig]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Zaanan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring the best treatment options for BRAF-mutant metastatic colon cancer]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2019</year>
<volume>121</volume>
<page-range>434-42</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
